AP
UTHR icon

Anchyra Partners’s United Therapeutics UTHR Stock Holding History

Anchyra Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
1,956
+4
+0.2% +$2.25K 0.25% 79
2026
Q1 		$1.16M Buy
1,952
+5
+0.3% +$2.49K 0.35% 56
2025
Q4 		$949K Buy
+1,947
New +$907K 0.29% 69

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Anchyra Partners's UTHR Position: Q2 2026 in Review

Anchyra Partners increased its United Therapeutics (UTHR) stake by 0.2% in Q2 2026, buying an estimated $2.25K and bringing the position to 1,956 shares worth $1.06M. The position accounts for 0.25% of the portfolio, ranked #79.

Anchyra Partners first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.16M in Q1 2026. 417 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Anchyra Partners held 1,956 shares of United Therapeutics worth $1.06M as of Q2 2026.
  • Anchyra Partners bought 4 United Therapeutics shares in Q2 2026, an estimated $2.25K.
  • United Therapeutics made up 0.25% of Anchyra Partners's portfolio in Q2 2026, its #79 holding.
  • Anchyra Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Anchyra Partners's United Therapeutics position peaked at $1.16M in Q1 2026.
  • 417 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.